Results 131 to 140 of about 20,108 (223)

PCAT6 Regulates IGF2BP1/PD‐L1 to Promote Immune Escape in Breast Cancer

The Journal of Gene Medicine, Volume 28, Issue 8, August 2026.
The lncRNA PCAT6 is upregulated in triple‐negative breast cancer (TNBC) and correlates with aggressive tumor features. Mechanistically, PCAT6 interacts with the RNA‐binding protein IGF2BP1 in the cytoplasm, enhancing IGF2BP1‐mediated stabilization of PD‐L1 mRNA and consequently upregulating PD‐L1 expression on tumor cells. Elevated PD‐L1 suppresses CD8+
Dingping Sun, Shanglong Sun, Jing Li, Liping Gu, Weijian Yang, Li Shang   +5 more
wiley   +1 more source

Regulatory mechanisms and therapeutic potential of N6-methyladenosine modification in retinal diseases (Review). [PDF]

Mol Med Rep
Zhang W, Chen J, Zhong J.
europepmc   +1 more source

Glucose Transporter 1 in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
As the quintessential facilitator of basal glucose uptake, glucose transporter 1 (GLUT1) is indispensable for maintaining systemic energy homeostasis. This graphical abstract delineates the multidimensional landscape of GLUT1 in normal physiology. It highlights its tissue‐specific metabolic roles—from fueling erythrocytes and fetal development to ...
Yi Tai, Zhihao Chen, Yuping Zhu, Weidong Han   +3 more
wiley   +1 more source

FUS is an N1- and N6-methyladenosine-binding protein. [PDF]

Nucleic Acids Res
Liang X, Zhao T, Dai X, Sun Y, Yuan J, Afzalpurkar S, Duong C, Yu A, Tang F, He X, Liu X, Chen X, Cao Z, Wang Y.   +13 more
europepmc   +1 more source

MAPK Inhibitor‐Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities

Cancer Science, Volume 117, Issue 8, Page 2050-2063, August 2026.
Melanoma response to MAPK inhibition progresses from drug‐sensitive cells to drug‐tolerant persister states, which enable survival through adaptive signaling, metabolic rewiring, and phenotypic plasticity. These persister cells serve as an intermediate reservoir from which resistant tumors ultimately emerge. ABSTRACT Though major advancements have been
Bhoomi Shah, Mackenzie M. Mayhew, Jacob Sellers, Russell G. Witt   +3 more
wiley   +1 more source

A bibliometric analysis of advances in N6‑methyladenosine research in colorectal cancer. [PDF]

Discov Oncol
Zhao L, Sun Y, Li J, Yang W, Wang Z, Yu B, Du L.   +6 more
europepmc   +1 more source

Lysine l‐Lactylation: Bridging Metabolism, Chromatin and Disease

Cell Proliferation, Volume 59, Issue 8, August 2026.
Enzymatic regulation of KL‐la. The enzymatic regulation of KL‐la involves two distinct pathways for L‐lactate accumulation: intracellular production through glycolysis‐derived pyruvate conversion by lactate dehydrogenase (LDH) or direct cellular uptake via monocarboxylate transporters (MCTs). These L‐lactate pools fuel two distinct lactylation pathways—
Anoosha Malik, Muhammad Dilawar, Junguang Liao, Jie Zheng, Qitao Qian, Ming Xu, Sisi Lin, Xiaobo Zhu, Qiuwei Ge, Limin Jin, Guiqian Chen   +10 more
wiley   +1 more source

Epitranscriptomic Stability-Variable Extents of N1-Methyladenosine to N6-Methyladenosine Conversion Under Different Experimental Conditions. [PDF]

Biomolecules
Shnaider FM, Kanan H, Patel S, Chiu NHL.
europepmc   +1 more source

Beyond Sequence: Posttranslational Remodeling of Antigens in Autoimmunity

Immunological Reviews, Volume 341, Issue 1, August 2026.
ABSTRACT Autoimmune responses are often attributed to failed tolerance to self‐proteins, yet protein expression alone cannot explain why certain antigens dominate disease, why autoreactivity emerges under stress, or why specific HLA alleles shape risk.
Cynthiya Shrestha, Holly M. Weisfelder, Thanh D. Do   +2 more
wiley   +1 more source

Profiles and roles of N6-methyladenosine modification in bovine oocyte maturation. [PDF]

BMC Genomics
Han T, Wang Z, Gan X, Yang Z, Wang W, Hu K, Zhu R, Li Y, Zhang Y, Cao Z.   +9 more
europepmc   +1 more source